Claims for Patent: 10,945,973

Summary for Patent: 10,945,973

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US16/983,873
Patent Claims:	1. A method of treating major depression, comprising orally administering a dosage form once a day or twice a day to a human being in need thereof for at least 8 consecutive days, wherein the dosage form contains dextromethorphan and bupropion as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion, wherein a total daily dose of about 200 mg to about 250 mg of the bupropion and a total daily dose of about 80 mg to about 110 mg of the dextromethorphan are orally administered to the human being; and wherein orally administering the dosage form is more effective than orally administering the same amount of the bupropion for 8 consecutive days in treating major depression. 2. The method of claim 1, wherein the total daily dose of the dextromethorphan is 90 mg of dextromethorphan hydrobromide or a molar equivalent amount of another form of dextromethorphan. 3. The method of claim 2, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, is orally administered twice a day. 4. The method of claim 3, wherein the dosage form is orally administered twice a day. 5. The method of claim 4, wherein the human being is an adult. 6. The method of claim 5, wherein the human being is suffering from treatment-resistant depression. 7. The method of claim 5, wherein the dosage form further comprises an excipient. 8. The method of claim 5, wherein the dosage form further comprises a binder. 9. The method of claim 5, wherein the dosage form further comprises a lubricant. 10. The method of claim 5, wherein the dosage form further comprises a disintegrating agent. 11. The method of claim 3, wherein the dosage form is orally administered twice a day for at least 14 days. 12. The method of claim 11, wherein the human being is an adult. 13. The method of claim 12, wherein the human being is suffering from treatment-resistant depression. 14. The method of claim 12, wherein the dosage form further comprises an excipient. 15. The method of claim 12, wherein the dosage form further comprises a binder. 16. The method of claim 12, wherein the dosage form further comprises a lubricant. 17. The method of claim 12, wherein the dosage form further comprises a disintegrating agent. 18. The method of claim 3, wherein the dosage form is orally administered twice a day for at least 30 days. 19. The method of claim 18, wherein the human being is suffering from treatment-resistant depression. 20. The method of claim 18, wherein the human being is an adult. 21. The method of claim 20, wherein the dosage form further comprises an excipient. 22. The method of claim 20, wherein the dosage form further comprises a binder. 23. The method of claim 20, wherein the dosage form further comprises a lubricant. 24. The method of claim 20, wherein the dosage form further comprises a disintegrating agent. 25. The method of claim 2, wherein the total daily dose of the dextromethorphan is orally administered in a single daily dose. 26. The method of claim 25, wherein the single daily dose of the dextromethorphan is orally administered for at least 14 days. 27. The method of claim 25, wherein the single daily dose of the dextromethorphan is orally administered for at least 30 days. 28. The method of claim 1, wherein the human being is suffering from treatment-resistant depression. 29. The method of claim 1, wherein the human being is an adult.